CY1124908T1 - Παραγωγο μορφινανης - Google Patents
Παραγωγο μορφινανηςInfo
- Publication number
- CY1124908T1 CY1124908T1 CY20221100041T CY221100041T CY1124908T1 CY 1124908 T1 CY1124908 T1 CY 1124908T1 CY 20221100041 T CY20221100041 T CY 20221100041T CY 221100041 T CY221100041 T CY 221100041T CY 1124908 T1 CY1124908 T1 CY 1124908T1
- Authority
- CY
- Cyprus
- Prior art keywords
- represent hydrogen
- heterocycle
- carbon atoms
- carbon atom
- hydrogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Τα παράγωγα μορφινάνης που αντιπροσωπεύονται με το γενικό τύπο (Ι) (όπου R1 αντιπροσωπεύει υδρογόνο, C1-10αλκύλ, κυκλοαλκυλαλκύλ όπου η κυκλοαλκύλ χαρακτηριστική ομάδα έχει 3-6 άτομα άνθρακα και η αλκυλένο χαρακτηριστική ομάδα έχει 1-5 άτομα άνθρακα, ή τα παρόμοια· R2 αντιπροσωπεύει ετερόκυκλο που συμπεριλαμβάνει τουλάχιστον ένα άτομο άνθρακα και 1-4 ετεροάτομα που επιλέγονται μεταξύ Ν, Ο και S ως συστατικό δακτυλιοειδή άτομα, με τουλάχιστον μία ομάδα γειτονικών δακτυλιοειδών ατόμων συστατικών που έχουν διπλό δεσμό, ο εν λόγω δε ετερόκυκλος επίσης συμπεριλαμβάνει τουλάχιστον μία όξο ομάδα ως υποκαταστάτη· Υ συνδέεται προς άτομο άνθρακα που είναι συστατικό δακτυλιοειδές άτομο της R2· R3· R4 και R5 αντιπροσωπεύουν υδρογόνο, υδρόξυ ή τα παρόμοια· R6a και R6b αντιπροσωπεύουν υδρογόνο ή τα παρόμοια· R7 και R8 αντιπροσωπεύουν υδρογόνο ή τα παρόμοια· R9 και R10 είναι οι ίδιες ή διαφορετικές, και αντιπροσωπεύουν υδρογόνο ή τα παρόμοια· Χ αντιπροσωπεύει Ο ή CH2· και Υ αντιπροσωπεύει C(=O)), παραλλαγές και στερεοϊσομερή των παραγώγων, φαρμακευτικώς αποδεκτά άλατα αυτών, και διαλυτώματα αυτών σύμφωνα προς την παρούσα εφεύρεση χρησιμοποιούνται ως αντιαγχωτικά φάρμακα, αντικαταθλιπτικά και τα παρόμοια.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015054079 | 2015-03-17 | ||
PCT/JP2016/058475 WO2016148232A1 (ja) | 2015-03-17 | 2016-03-17 | モルヒナン誘導体 |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1124908T1 true CY1124908T1 (el) | 2023-01-05 |
Family
ID=56919074
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20221100041T CY1124908T1 (el) | 2015-03-17 | 2022-01-18 | Παραγωγο μορφινανης |
Country Status (24)
Country | Link |
---|---|
US (4) | US10442802B2 (el) |
EP (2) | EP3974430A1 (el) |
JP (4) | JP6692345B2 (el) |
KR (2) | KR20230104767A (el) |
CN (3) | CN113292558A (el) |
AU (2) | AU2016234222C1 (el) |
BR (1) | BR112017019805B1 (el) |
CA (1) | CA2979023C (el) |
CY (1) | CY1124908T1 (el) |
DK (1) | DK3272750T3 (el) |
ES (1) | ES2904511T3 (el) |
HK (1) | HK1249900A1 (el) |
HU (1) | HUE057266T2 (el) |
IL (1) | IL254473B (el) |
MA (1) | MA41790B1 (el) |
MX (2) | MX2021008741A (el) |
MY (1) | MY197742A (el) |
PH (1) | PH12017501655A1 (el) |
PL (1) | PL3272750T3 (el) |
RU (1) | RU2762567C2 (el) |
SG (2) | SG10201907667RA (el) |
TW (2) | TWI775723B (el) |
WO (1) | WO2016148232A1 (el) |
ZA (1) | ZA201706882B (el) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018030382A1 (ja) | 2016-08-09 | 2018-02-15 | 国立大学法人 筑波大学 | モルヒナン誘導体 |
AU2017327304B9 (en) * | 2016-09-16 | 2023-10-12 | Nippon Chemiphar Co., Ltd. | Use of morphinan derivative for therapeutic treatment of opioid δ receptor agonist-related disease |
JP7283711B2 (ja) * | 2016-10-03 | 2023-05-30 | 学校法人星薬科大学 | モルヒナン誘導体を含む医薬組成物及びその鎮痛剤への使用 |
AU2020317503A1 (en) * | 2019-07-19 | 2022-02-10 | Nippon Chemiphar Co., Ltd. | Method for producing phenol derivative |
AU2020318159A1 (en) | 2019-07-19 | 2022-02-10 | Nippon Chemiphar Co., Ltd. | Method for producing morphinan derivative |
CA3192609A1 (en) | 2020-08-28 | 2022-03-03 | Nippon Chemiphar Co., Ltd. | Method for preparing morphinan derivative having diaryl ether skeleton using novel copper catalyst |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005231995A (ja) | 1999-12-22 | 2005-09-02 | Meiji Seika Kaisha Ltd | オピオイドδ受容体アゴニスト/アンタゴニストとして有用なスピロ化合物 |
DE10161963A1 (de) | 2001-12-17 | 2003-07-03 | Johannes Schuetz | 6-Aminomorphinanderivate, Herstellungsverfahren dafür und deren Verwendung |
AR044010A1 (es) | 2003-04-11 | 2005-08-24 | Janssen Pharmaceutica Nv | Uso de derivados de 4-fenil-4- [1h-imidazol-2-il]- piperidina sustituidos como agonistas delta opioideos no peptidos selectivos, con actividad antidepresiva y ansiolitica |
WO2006107254A1 (en) | 2005-04-04 | 2006-10-12 | Astrazeneca Ab | Novel diazaspiroalkanes and their use for treatment of ccr8 mediated diseases |
WO2008001859A1 (fr) | 2006-06-30 | 2008-01-03 | School Juridical Person Kitasato Gakuen | AGONISTE DES RÉCEPTEURS δ DES OPIOÏDES |
WO2009033084A1 (en) | 2007-09-06 | 2009-03-12 | Array Biopharma Inc. | Pyrazolo-pyridines as tyrosine kinase inhibitors |
EP2493878B1 (en) | 2009-10-30 | 2016-10-12 | Janssen Pharmaceutica NV | Pyrazines as delta opioid receptor modulators |
US9227971B2 (en) | 2010-01-19 | 2016-01-05 | Merck Sharp & Dohme Corp. | Pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors |
ES2604931T3 (es) | 2010-12-23 | 2017-03-10 | Phoenix Pharmalabs, Inc. | Nuevos morfinanos útiles como analgésicos |
JP2014073964A (ja) | 2011-01-28 | 2014-04-24 | Kitasato Institute | モルヒナン誘導体 |
JP6061857B2 (ja) * | 2011-09-09 | 2017-01-18 | 学校法人北里研究所 | モルヒナン誘導体 |
WO2014021273A1 (ja) | 2012-07-30 | 2014-02-06 | 学校法人北里研究所 | モルヒナン誘導体 |
JP6163210B2 (ja) | 2012-12-14 | 2017-07-12 | パーデュー、ファーマ、リミテッド、パートナーシップ | 窒素含有モルフィナン誘導体およびその使用 |
CA2908805A1 (en) * | 2013-03-08 | 2014-09-12 | The Kitasato Institute | Morphinan derivative |
AU2017327304B9 (en) | 2016-09-16 | 2023-10-12 | Nippon Chemiphar Co., Ltd. | Use of morphinan derivative for therapeutic treatment of opioid δ receptor agonist-related disease |
-
2016
- 2016-03-17 MY MYPI2017703345A patent/MY197742A/en unknown
- 2016-03-17 SG SG10201907667RA patent/SG10201907667RA/en unknown
- 2016-03-17 SG SG11201707427TA patent/SG11201707427TA/en unknown
- 2016-03-17 US US15/558,026 patent/US10442802B2/en active Active
- 2016-03-17 PL PL16765061T patent/PL3272750T3/pl unknown
- 2016-03-17 MX MX2021008741A patent/MX2021008741A/es unknown
- 2016-03-17 ES ES16765061T patent/ES2904511T3/es active Active
- 2016-03-17 CN CN202110577382.4A patent/CN113292558A/zh active Pending
- 2016-03-17 DK DK16765061.3T patent/DK3272750T3/da active
- 2016-03-17 KR KR1020237022162A patent/KR20230104767A/ko not_active Application Discontinuation
- 2016-03-17 JP JP2017506606A patent/JP6692345B2/ja active Active
- 2016-03-17 MX MX2017011824A patent/MX2017011824A/es unknown
- 2016-03-17 MA MA41790A patent/MA41790B1/fr unknown
- 2016-03-17 CN CN202110578658.0A patent/CN113292559B/zh active Active
- 2016-03-17 WO PCT/JP2016/058475 patent/WO2016148232A1/ja active Application Filing
- 2016-03-17 CN CN201680016083.0A patent/CN107614500B/zh active Active
- 2016-03-17 RU RU2017134286A patent/RU2762567C2/ru active
- 2016-03-17 AU AU2016234222A patent/AU2016234222C1/en active Active
- 2016-03-17 CA CA2979023A patent/CA2979023C/en active Active
- 2016-03-17 EP EP21203556.2A patent/EP3974430A1/en active Pending
- 2016-03-17 KR KR1020177029778A patent/KR102551969B1/ko active IP Right Grant
- 2016-03-17 EP EP16765061.3A patent/EP3272750B1/en active Active
- 2016-03-17 TW TW105108248A patent/TWI775723B/zh active
- 2016-03-17 HU HUE16765061A patent/HUE057266T2/hu unknown
- 2016-03-17 TW TW111126713A patent/TWI778933B/zh active
- 2016-03-17 BR BR112017019805-3A patent/BR112017019805B1/pt active IP Right Grant
-
2017
- 2017-09-11 PH PH12017501655A patent/PH12017501655A1/en unknown
- 2017-09-13 IL IL254473A patent/IL254473B/en unknown
- 2017-10-11 ZA ZA2017/06882A patent/ZA201706882B/en unknown
-
2018
- 2018-07-19 HK HK18109334.6A patent/HK1249900A1/zh unknown
-
2019
- 2019-07-19 US US16/517,081 patent/US10995092B2/en active Active
-
2020
- 2020-04-10 JP JP2020071041A patent/JP2020117533A/ja not_active Ceased
- 2020-10-13 US US17/069,589 patent/US11643411B2/en active Active
- 2020-11-18 AU AU2020270503A patent/AU2020270503C9/en active Active
-
2022
- 2022-01-18 CY CY20221100041T patent/CY1124908T1/el unknown
- 2022-03-18 JP JP2022044083A patent/JP7375076B2/ja active Active
-
2023
- 2023-01-09 US US18/094,687 patent/US20230159530A1/en active Pending
- 2023-10-25 JP JP2023183221A patent/JP2024010098A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1124908T1 (el) | Παραγωγο μορφινανης | |
CY1124173T1 (el) | Υποκατεστημενες ενωσεις αμινοπουρινης, συνθεσεις αυτων και μεθοδοι θεραπειας με αυτες | |
CY1123443T1 (el) | Οξεα καρβαμοϋλοξυμεθυλ-τριαζολ-κυκλοεξυλιου ως ανταγωνιστες lpa | |
AR109348A1 (es) | Sulfonilureas y compuestos relacionados y sus usos | |
DOP2016000299A (es) | Derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y su uso como inhibidores ido1 | |
CY1124620T1 (el) | Οξυστερολες και μεθοδοι χρησης αυτων | |
CO6420340A2 (es) | Derivados de benzofurano | |
CY1123154T1 (el) | Παραγοντας ενισχυσης της επιδρασης αποκαταστασης μετα απο νευρικη βλαβη που περιλαμβανει ενα παραγωγο αλκυλαιθερα ή ενα αλας αυτου | |
AR110789A1 (es) | Compuestos moduladores del receptor de hidrocarburos de arilo (ahr) | |
AR110790A1 (es) | Compuestos moduladores del receptor de hidrocarburos de arilo (ahr) | |
CY1111493T1 (el) | Παραγωγα πυραζολιου ως τροποποιητες πρωτεϊνοκινασης | |
CY1115809T1 (el) | Φουραζανοβενζιμιδαζολες ως προφαρμακα για τη θεραπεια νεοπλασματικων ή αυτοανοσων ασθενειων | |
CY1124795T1 (el) | Συνθεσεις και μεθοδοι για τη θεραπεια και προφυλαξη λοιμωξεων χειρουργικης θεσης | |
CL2019001495A1 (es) | Compuestos de heterociclo tetracíclicos útiles como inhibidores de la integrasa del vih. | |
AR112274A1 (es) | Compuestos bicíclicos de cetona y sus métodos de uso | |
AR109735A1 (es) | Método para la síntesis de derivado de 3-fenil-2,3,4,8,9,10-hexahidropirano[2,3-f]cromeno e isómero óptico del mismo | |
CO2018010787A2 (es) | Compuesto de griseofulvina | |
PE20190964A1 (es) | Inhibidores de dopamina-b-hidroxilasa penetrantes de la barrera hematoencefalica | |
MA50093B1 (fr) | Composé pentacyclique | |
CY1123114T1 (el) | Νεες ενωσεις χρησιμες ως παραγοντες διανοιξης διαυλων καλιου | |
CY1124051T1 (el) | Θεραπεια νευρολογικων διαταραχων | |
AR109467A1 (es) | Compuestos, procedimiento de obtención de los compuestos, composición farmacéutica, uso de los compuestos y método de tratamiento de desórdenes psiquiátricos y/o trastornos del sueño | |
WO2016097657A3 (fr) | Dimères polyaromatiques, leur procédé de préparation et utilisation | |
TW201613933A (en) | Long acting HIV protease inhibitor | |
AR109042A1 (es) | COMPUESTOS MODULARES DE RORg |